June 4, 2015

Sandoz has announced that it is introducing guanfacine hydrochloride extended-release tablets, a generic version of Intuniv, in 1-, 2-, 3- and 4-mg dosages.

June 2, 2015

The latest addition to Teva’s roster of medication is its generic version of Intuniv (guanfacine) extended release tablets, a non-stimulant meant to treat attention deficit hyperactivity disorder.

May 28, 2015

Camber Pharmaceuticals on Thursday announced that it had launched antipsychotic drug aripiprazole — a generic version of Abilify — in 2-, 5-, 10-, 15-, 20- and 30-mg dosage strength tablets. 

April 29, 2015

Teva Pharmaceutical announced the launch of aripiprazole tablets in 2-, 5-, 10-, 15, 20- and 30-mg strengths in the United States.

March 13, 2015

Actavis on Friday announced that the Food and Drug Administration approved Saphris for the treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients.

February 2, 2015

The Food and Drug Administration announced that it has expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults, making it the first FDA-approved medicine to treat this condition.

 

December 29, 2014

Actavis and Adamas Pharmaceuticals last week announced that the Food and Drug Administration approved Namzaric. According to the companies, the drug is used to treat moderate to severe dementia of the Alzheimer's type in patients stablized on memantine hydrochloride and donepezil hydrochloride.

 

November 13, 2014

 Janssen Pharmaceuticals announced that the Food and Drug Administration approved the company's supplemental new drug application for the once-monthly Invega Sustenna (paliperidone palmitate), an antipsychotic used to treat schizoaffective disorder as either monotherapy or adjunctive therapy. 

October 21, 2014

Over-the-counter painkillers and anti-inflammatory drugs may also be effective in the treatment of people suffering from depression.

 

September 9, 2014

Several organizations last week formed the Coalition to Prevent ADHD Medication Misuse to help prevent misuse, abuse and diversion of ADHD prescription stimulant medication. 

August 12, 2014

In the largest study of its kind, researchers last week suggested that in older people, not getting enough vitamin D may double the risk of developing dementia and Alzheimer's disease. 

July 16, 2014

Beauty brand philosophy has announced the launch of the hope & grace initiative to support mental health. Through the hope & grace initiative, philosophy will dedicate 1% of all sales across all products to organizations working to empower women through the promotion, prevention and treatment of mental health.

April 9, 2014

According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children.

March 3, 2014

Teva Pharmaceutical Industries announced the launch of Adasuve (loxapine) inhalation powder in a 10-mg dosage. The drug is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

February 27, 2014

A long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy, UCLA announced earlier this week.

February 26, 2014

A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder.

January 22, 2014

Takeda Pharmaceuticals and Lundbeck announced the availability of Brintellix (vortioxetine), a once-daily oral antidepressant for treatment of major depressive disorder in adults.

December 18, 2013

A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

December 2, 2013

The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

November 21, 2013

The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.

November 21, 2013

Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

November 18, 2013

Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.

October 31, 2013

A personalized medicine company said a new study justifies clinical use of pharmacogenomic testing to help predict patients' response to psychiatric medications and improve treatment outcomes.